Work

Supplementary Data from OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Year: 2023

Type: supplementary-materials

Abstract: This file contains Supplementary Methods, Supplementary Figures and Supplementary Tables

DOI: 10.1158/1078-0432.22471269

Authors: Kathryn Evans, JianXin Duan, Tara Pritchard, Connor D. Jones, Lisa McDermott, Zhaohui Gu, Cara E. Toscan, Narimanne El-Zein, Chelsea Mayoh, Stephen W. Erickson, Yuelong Guo, Fanying Meng, Donald Jung, Komal S. Rathi, Kathryn G. Roberts, Charles G. Mullighan, Chi-Sheng Shia, Tillman Pearce, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock

Institutions: UNSW Sydney, Children's Cancer Institute Australia, St. Jude Children's Research Hospital, RTI International, Children's Hospital of Philadelphia, National Institutes of Health, National Cancer Institute

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361887370

Cites:

Cited by:

Related to: 10